Forbes November 14, 2024
Ge Bai

The Inflation Reduction Act of 2022 introduced significant changes to the Medicare Part D prescription drug program, affecting tens of millions of seniors and other Medicare beneficiaries. Early evidence has now emerged, offering the public a glimpse into the law’s scorecard.

The law changed certain benefit designs for Medicare Part D standalone prescription drug plans, including a lower cap on out-of-pocket spending and a new cap on premium growth rates. These changes were initially estimated to cost taxpayers $30 billion over a decade.

The law also introduced price controls for prescription drugs under Medicare, which were anticipated to save taxpayers $160 billion over ten years. Congress used the projected $130 billion net savings to fund green energy initiatives.

However, a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
CMS Launches New Program for Mental Health, OUD Treatment
How Medicare Negotiated Drug Prices Compare to Other Countries
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Innovating Without Compromising Integration: Considerations For Medicare
How the Federal Government Could Push People Toward Medicare Advantage – And Replace Traditional Medicare

Share This Article